After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential

Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.

Schizophrenia
Alkermes is seeing promise in the early launch metrics for Lybalvi

Alkermes plc is seeing promise in the early launch metrics for its oral atypical antipsychotic combination tablet Lybalvi (olanzapine/samidorphan), and said that product combined with its established neuropsychiatric therapy portfolio gives it a differentiated commercial profile as its R&D efforts also move into oncology.

Approved by the US Food and Drug Administration last June after COVID-19-related site-inspection delays scuttled its first approval date in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business